In This Article:
Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced or recurrent cervical cancer that progressed on or following chemotherapy.
This is the first approval of an antibody-drug conjugate (ADC) for cervical cancer patients in the country.
The approval is grounded on the open-label Phase III innovaTV 301 clinical trial data that assessed the safety and efficacy of the therapy against chemotherapy.
The trial comprised 502 participants, 101 of whom were Japanese.
It met the overall survival (OS) goal, which was its primary endpoint, showing a 30% decrease in the mortality risk against chemotherapy.
Genmab chief development officer and executive vice-president Judith Klimovsky stated: “As a company, we understand the urgent need of patients with advanced cervical cancer whose disease has progressed.
“This approval marks an important step forward in transforming the treatment paradigm in Japan, ultimately bringing new hope and possibility to patients and their loved ones.”
The trial was conducted by Seagen in partnership with Genmab, the Gynecologic Oncology Group (GOG) Foundation and the European Network of Gynaecological Oncological Trial Groups, along with other international gynaecological oncology co-operative groups.
Pfizer acquired Seagen in December 2023.
Tivdak comprises Genmab’s human monoclonal antibody directed to tissue factor (TF) with the ADC technology of Pfizer, which leverages a protease-cleavable linker covalently attaching the microtubule-disrupting agent monomethyl auristatin E (MMAE) to the antibody.
Genmab and Pfizer jointly developed and commercialised the antibody worldwide, sharing profits and expenses under their agreement.
In Japan and global regions other than China and the US, Genmab spearheads commercialisation for previously treated recurrent or metastatic cervical cancer.
"Genmab’s Tivdak approved in Japan for advanced cervical cancer" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.